Does inchinkoto, a herbal medicine, have hepatoprotective effects in major hepatectomy? A prospective randomized study

HPB

Volumn 17, Issue 5, 2015, Pages 461-469

  Mizutani, Tetsushi ^a   Yokoyama, Yukihiro ^a   Kokuryo, Toshio ^a   Ebata, Tomoki ^a   Igami, Tsuyoshi ^a   Sugawara, Gen ^a   Nagino, Masato ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; HEME OXYGENASE 1; INCHINKOTO; PLACEBO; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; CYCLIC AMP PHOSPHODIESTERASE; HERBACEOUS AGENT; INCHINKO-TO;

AGED; ANTIOXIDANT ACTIVITY; ARTICLE; BILIRUBIN BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GENE EXPRESSION; HERBAL MEDICINE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENCE; LIVER FAILURE; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER ISCHEMIA; LIVER PROTECTION; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OPERATION DURATION; OPERATIVE BLOOD LOSS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UPREGULATION; ANTAGONISTS AND INHIBITORS; LIVER DISEASES; PHYTOTHERAPY; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROCEDURES;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; AGED; DRUGS, CHINESE HERBAL; FEMALE; HEPATECTOMY; HUMANS; LIVER DISEASES; MALE; PHYTOTHERAPY; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROSPECTIVE STUDIES;

EID: 84927568902     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/hpb.12384     Document Type: Article

References (29)

1. Fondevila C, Shen XD, Tsuchiyashi S, Yamashita K, Csizmadia E, Lassman C, et al. (2004) Biliverdin therapy protects rat livers from ischemia and reperfusion injury. Hepatology 40: 1333-1341.
2. Muratore A, Ribero D, Ferrero A, Bergero R, Capussotti L,. (2003) Prospective randomized study of steroids in the prevention of ischaemic injury during hepatic resection with pedicle clamping. Br J Surg 90: 17-22.
3. Beck-Schimmer B, Breitenstein S, Urech S, De Conno E, Wittlinger M, Puhan M, et al. (2008) A randomized controlled trial on pharmacological preconditioning in liver surgery using a volatile anesthetic. Ann Surg 248: 909-918.
4. Fan ST, Lo CM, Lai EC, Chu KM, Liu CL, Wong J,. (1994) Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med 331: 1547-1552.
5. Fisette A, Hassanain M, Metrakos P, Doi SA, Salman A, Schricker T, et al. (2012) High-dose insulin therapy reduces postoperative liver dysfunction and complications in liver resection patients through reduced apoptosis and altered inflammation. J Clin Endocrinol Metab 97: 217-226.
6. Yamamoto M, Miura N, Ohtake N, Amagaya S, Ishige A, Sasaki H, et al. (2000) Genipin, a metabolite derived from the herbal medicine Inchin-ko-to, and suppression of Fas-induced lethal liver apoptosis in mice. Gastroenterology 118: 380-389.
7. Yamamoto M, Ogawa K, Morita M, Fukuda K, Komatsu Y,. (1996) The herbal medicine Inchin-ko-to inhibits liver cell apoptosis induced by transforming growth factor beta 1. Hepatology 23: 552-559.
8. Shoda J, Miura T, Utsunomiya H, Oda K, Yamamoto M, Kano M, et al. (2004) Genipin enhances Mrp2 (Abcc2)-mediated bile formation and organic anion transport in rat liver. Hepatology 39: 167-178.
9. Watanabe S, Yokoyama Y, Oda K, Kokuryo T, Shoda J, Okada K, et al. (2009) Choleretic effect of inchinkoto, a herbal medicine, on livers of patients with biliary obstruction due to bile duct carcinoma. Hepatol Res 39: 247-255.
10. Okada K, Shoda J, Kano M, Suzuki S, Ohtake N, Yamamoto M, et al. (2007) Inchinkoto, a herbal medicine, and its ingredients dually exert Mrp2/MRP2-mediated choleresis and Nrf2-mediated antioxidative action in rat livers. Am J Physiol Gastrointest Liver Physiol 292: G1450-G1463.
11. Kawai K, Yokoyama Y, Kokuryo T, Watanabe K, Kitagawa T, Nagino M,. (2010) Inchinkoto, an herbal medicine, exerts beneficial effects in the rat liver under stress with hepatic ischemia-reperfusion and subsequent hepatectomy. Ann Surg 251: 692-700.
12. Jung KA, Kwak MK,. (2010) The Nrf2 system as a potential target for the development of indirect antioxidants. Molecules 15: 7266-7291.
13. Schulz KF, Altman DG, Moher D,. (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 340: c332.
14. Yokoyama Y, Nishio H, Ebata T, Igami T, Sugawara G, Nagino M,. (2010) Value of indocyanine green clearance of the future liver remnant in predicting outcome after resection for biliary cancer. Br J Surg 97: 1260-1268.
15. Nagino M, Kamiya J, Nishio H, Ebata T, Arai T, Nimura Y,. (2006) Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Ann Surg 243: 364-372.
16. Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, Nagino M,. (2012) Portal vein embolization before extended hepatectomy for biliary cancer: current technique and review of 494 consecutive embolizations. Dig Surg 29: 23-29.
17. Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R, et al. (2011) Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery 149: 713-724.
18. Rahbari NN, Reissfelder C, Koch M, Elbers H, Striebel F, Buchler MW, et al. (2011) The predictive value of postoperative clinical risk scores for outcome after hepatic resection: a validation analysis in 807 patients. Ann Surg Oncol 18: 3640-3649.
19. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR,. (1999) Guideline for prevention of surgical site infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control 27: 97-132.
20. Dindo D, Demartines N, Clavien PA,. (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240: 205-213.
21. Takayama Y, Kokuryo T, Yokoyama Y, Nagino M, Nimura Y, Senga T, et al. (2008) MEK inhibitor enhances the inhibitory effect of imatinib on pancreatic cancer cell growth. Cancer Lett 264: 241-249.
22. Yamaguchi T, Terakado M, Horio F, Aoki K, Tanaka M, Nakajima H,. (1996) Role of bilirubin as an antioxidant in an ischemia-reperfusion of rat liver and induction of heme oxygenase. Biochem Biophys Res Commun 223: 129-135.
23. Hsu YC, Chou TY, Chen CF, Wang D, Su CL, Hu RT,. (2008) Rat liver ischemia/reperfusion induced proinflammatory mediator and antioxidant expressions analyzed by gene chips and real-time polymerase chain reactions. Transplant Proc 40: 2156-2158.
24. Asakawa T, Yagi M, Tanaka Y, Asagiri K, Kobayashi H, Egami H, et al. (2012) The herbal medicine Inchinko-to reduces hepatic fibrosis in cholestatic rats. Pediatr Surg Int 28: 379-384.
25. Mase A, Makino B, Tsuchiya N, Yamamoto M, Kase Y, Takeda S, et al. (2010) Active ingredients of traditional Japanese (kampo) medicine, inchinkoto, in murine concanavalin A-induced hepatitis. J Ethnopharmacol 127: 742-749.
26. Imanishi Y, Maeda N, Otogawa K, Seki S, Matsui H, Kawada N, et al. (2004) Herb medicine Inchin-ko-to (TJ-135) regulates PDGF-BB-dependent signaling pathways of hepatic stellate cells in primary culture and attenuates development of liver fibrosis induced by thioacetamide administration in rats. J Hepatol 41: 242-250.
27. Kobayashi H, Horikoshi K, Yamataka A, Lane GJ, Yamamoto M, Miyano T,. (2001) Beneficial effect of a traditional herbal medicine (inchin-ko-to) in postoperative biliary atresia patients. Pediatr Surg Int 17: 386-389.
28. Kaiho T, Tsuchiya S, Yanagisawa S, Takeuchi O, Togawa A, Okamoto R, et al. (2008) Effect of the herbal medicine Inchin-Ko-To for serum bilirubin in hepatectomized patients. Hepatogastroenterology 55: 150-154.
29. Bilzer M, Paumgartner G, Gerbes AL,. (1999) Glutathione protects the rat liver against reperfusion injury after hypothermic preservation. Gastroenterology 117: 200-210.